Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for LS-174T Cells (Colon Adenocarcinoma Cell, CL-188)
- Proprietary cationic lipids formulation
Kit includes Transfection Enhancer reagent
Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
Work in the presence of serum
A proven reagent for establishing stable cell lines
Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download LS174 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for LS174T cells transfection kit: [PPT]
- UPC/GTIN/EAN: 860002089786
Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems
Reagent exhibits at least 92% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems LS174T Transfection Protocol: [PDF]
Download MSDS: [PDF]
LS-174T Cell Line:
Colorectal cancer cell lines represent accurate molecular models of primary carcinomas and have proven to be potent tools in preclinical colon cancer research. The LS 174T epithelial cell line was isolated from a 58-year-old Caucasian female with colorectal adenocarcinoma and produces high amounts of carcinoembryonic antigen (CEA). In addition to being positive for the expression of different oncogenes, such as c-myc, N-myc, H-ras, N-ras, Myb, and fos, the LS 174T cell line possesses abundant microvilli and vacuoles. LS 174T cells are positive for mRNA expression; however, they are negative for p53 antigen expression. This cell line is commonly used for oncological research as these cells produce vast amounts of carcinoembryonic antigen, a tumor marker. Altogen Biosystems supplies multiple in vitro transfection kits, including the cationic lipids formulation LS 174T transfection reagent kit for human colon cancer cells. The LS 174T reagent is compatible with both standard and reverse transfection methods, yielding very high transfection efficiency, as indicated by qRT-PCR.
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the LS174T cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in LS-174T cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into LS-174T cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides preoptimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6842)
- 1.5 ml (Catalog #6843)
- 1.5 ml CRISPR (Catalog #2168)
- 8.0 ml (Catalog #7058)